Cancer proteomics: from biomarker discovery to signal pathway profiling.
In the post-genomic era of science, the field of proteomics promises the discovery of new molecular targets for therapy, biomarkers for early detection, and new endpoints for therapeutic efficacy and toxicity. Patient-specific targeted therapeutics with reduced toxicity and increased efficacy, the u...
| Publicado en: | Cancer Journal Vol. 7; no. 1; pp. 69 - 70 |
|---|---|
| Autores principales: | , , |
| Formato: | Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
Jan/Feb2001
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106092725&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106092725 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15289117 4U5 jtl: Cancer Journal issn: 15289117 maglogo: N pubinfo: dt: Jan/Feb2001 vid: 7 iid: 1 pid: 5086 pub: Lippincott Williams & Wilkins place: Baltimore, Maryland artinfo: ui: 106092725 2009433538 NLM11269650 106092725 ppf: 69 ppct: 1 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Cancer proteomics: from biomarker discovery to signal pathway profiling. aug: au: Bichsel VE Liotta LA Petricoin EF III sug: subj: Neoplasms Proteins Analysis Signal Transduction Physiology Tumor Markers, Biological Analysis Biological Markers Analysis Cell Separation Electrophoresis Methods Neoplasms Metabolism Peptide Mapping Methods Proteins Metabolism Proteomics Tumor Markers, Biological Metabolism ab: In the post-genomic era of science, the field of proteomics promises the discovery of new molecular targets for therapy, biomarkers for early detection, and new endpoints for therapeutic efficacy and toxicity. Patient-specific targeted therapeutics with reduced toxicity and increased efficacy, the ultimate goal for rational drug development, can only be achieved if direct analyses of the tissue cells in the actual human malignancy are analyzed. To that end, technologies such as Laser Capture Microdissection (LCM), is providing unparalleled access to the purified diseased human cells directly from tissue specimens. However, limited availability of patient material is a challenge towards the development of new highly sensitive proteomic methodologies. Two-dimensional gel electrophoresis (2D-PAGE), still the mainstay of most proteomic analysis of disease, is being complemented, and in some instances replaced by new exciting approaches to multiparametric protein characterization. The use of rapid, high throughput mass spectrometric-based fingerprints of peptides and proteins may prove to be valuable for new molecular classification of human tumors and disease stages. Coupled with LCM, high-density protein arrays, antibody arrays, and small molecular arrays, could have a substantial impact on proteomic profiling of human malignancies. Finally, detailed real-time knowledge about the states of intracellular signaling circuitry and pathways in the normal and malignant cells before, during and after therapy will yield invaluable information about mechanism of action and efficacy of existing and novel therapeutics for the treatment of human cancer. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|